Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma

Part of paid clinical trials in Sacramento, California.

Sponsor
University of California, Davis
Study ID
NCT00795665
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
  • carmustine — DRUG
    BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with carmustine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with carmustine works in treating patients with relapsed or progressive high-grade glioma.

Key Dates

First listed
Nov 21, 2008
Start date
Jun 30, 2008
Status verified
May 2020
Primary completion
Dec 31, 2015
Completion
Dec 31, 2015

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab and Carmustine

Primary Outcome Measure

Progression-free Survival [ Time Frame: Time from first day of treatment to the first observation of disease progression or death due to any cause (up to 7 years). ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California Davis Cancer CenterSacramentoCalifornia95817-

Find similar trials in Sacramento, CA

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
University of California Davis Cancer Center· Sacramento, CA

Related Studies